TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER (TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER).
Provides exogenous amino acids and dextrose to meet caloric and protein requirements in patients who cannot tolerate enteral nutrition. Amino acids are used for protein synthesis and as substrates for gluconeogenesis and other metabolic pathways.
| Metabolism | Amino acids undergo oxidation, transamination, and urea cycle; dextrose is metabolized via glycolysis and the Krebs cycle. Excretion of nitrogen occurs as urea via the kidneys. |
| Excretion | Amino acids and dextrose are metabolized; excess nitrogen is excreted primarily as urea in urine. Dextrose is metabolized to CO2 and water. Biliary/fecal: negligible. |
| Half-life | Amino acids: not applicable (endogenous metabolites). Dextrose: <15 minutes; clinical context: continuous infusion required to maintain glucose homeostasis. |
| Protein binding | Amino acids: minimal (<10% bound to albumin); dextrose: not bound. |
| Volume of Distribution | Amino acids: ~0.2-0.4 L/kg (confined to extracellular fluid); dextrose: ~0.2 L/kg (distributes in total body water). |
| Bioavailability | Intravenous: 100% (only route of administration). |
| Onset of Action | Intravenous: immediate (within minutes) for caloric and nitrogen provision; metabolic effects begin promptly upon infusion. |
| Duration of Action | Duration depends on infusion rate and metabolic demand; continuous infusion maintains steady state. After cessation, effects decline rapidly (minutes to hours). |
| Molecular Weight | 180.16 |
Intravenous infusion: 500 mL to 1000 mL over 24 hours, titrated to provide 2.75% amino acids and 20% dextrose as part of parenteral nutrition. Rate based on glucose tolerance and metabolic needs.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <50 mL/min: Reduce total nitrogen intake by 50% and monitor serum urea and electrolytes. GFR <20 mL/min: Use with caution; consider alternative amino acid formulations. No specific dose adjustment for dextrose component. |
| Liver impairment | Child-Pugh Class B or C: Reduce amino acid component to 1-2 g/kg/day, use branched-chain enriched formula if available. Dextrose may require reduction if hyperglycemia present. |
| Pediatric use | Weight-based: Amino acids 0.5-2 g/kg/day; dextrose 5-20 mg/kg/min. Begin at lower end and titrate to metabolic parameters. Infuse via central line for concentrations >10% dextrose. |
| Geriatric use | Start at lower infusion rates (0.5-1 mL/kg/h) due to increased risk of fluid overload and hyperglycemia. Monitor renal function and electrolytes closely. Use with caution in heart failure or renal impairment. |
| 1st trimester | Contains dextrose and amino acids; no teratogenic risk known; use only if clearly needed. |
| 2nd trimester | Monitor maternal glucose and electrolytes; no fetal risk known. |
| 3rd trimester | Monitor for fluid overload; no fetal risk known. |
Clinical note
Comprehensive clinical and safety monograph for TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER (TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER).
| Placental transfer | Dextrose transfers freely; amino acids actively transported; both cross placenta. |
| Breastfeeding | Excretion into breast milk unknown; dextrose and amino acids are natural constituents; use with caution. |
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | TRAVASOL 2.75% IN DEXTROSE 20% is a combination of amino acids and dextrose for parenteral nutrition. Dextrose at high doses may cause fetal hyperglycemia and hyperinsulinemia, but no direct teratogenic effects are established. Amino acids are essential nutrients and not known to be teratogenic. However, the components are at high concentrations; use in pregnancy only if clearly needed. |
| Fetal Monitoring | Monitor maternal blood glucose, electrolytes, fluid balance, and liver function. Fetal monitoring for signs of hyperglycemia or growth disturbances. Assess maternal weight gain and nutritional status. |
| Fertility Effects | No known adverse effects on fertility from components. Dextrose and amino acids are essential for normal reproductive function. Inadequate nutrition may impair fertility; supplementation may aid. |
■ FDA Black Box Warning
Not intended for use in patients with severe hepatic disease, uremia, or metabolic disorders involving amino acid metabolism.
| Serious Effects |
Hypersensitivity to any componentHyperglycemia uncontrolledSevere electrolyte disordersSevere hepatic insufficiencyIntracranial or spinal hemorrhageSevere azotemia (amino acid component)
| Precautions | Monitor serum electrolyte concentrations, fluid balance, and acid-base status, Risk of hyperglycemia, especially in patients with diabetes mellitus, Hepatic and renal function should be assessed before and during therapy, Intravenous administration requires strict aseptic technique |
| Food/Dietary | No direct food interactions as this product is administered intravenously. However, oral intake should be coordinated with the nutrition support team to avoid overfeeding or electrolyte disturbances. If the patient is able to eat, monitor for decreased appetite and adjust parenteral nutrition accordingly. |
| Clinical Pearls | Travasol 2.75% in Dextrose 20% is a parenteral nutrition formulation containing amino acids and a high dextrose concentration (20%). Monitor serum glucose closely due to hyperglycemia risk, especially in diabetic or critically ill patients. Administer via central line only due to high osmolality (approximately 1300 mOsm/L). Check for electrolyte imbalances, particularly potassium and phosphate, as refeeding syndrome can occur. Do not add medications directly to the container; use a dedicated Y-site with compatibility confirmation. For peripheral administration, consider a lower dextrose concentration (≤10%) to avoid phlebitis. |
| Patient Advice | This solution provides nutrition intravenously. Tell your nurse immediately if you experience pain, redness, or swelling at the infusion site. · You may need regular blood tests to monitor your blood sugar, electrolytes, and liver function. · Report any symptoms of high blood sugar such as excessive thirst, frequent urination, or headache. · Do not eat or drink unless approved by your care team, as this formulation is meant to replace or supplement oral intake. · This infusion must be given through a special large vein catheter; do not attempt to adjust the infusion rate. |
Loading safety data…